RSV Vaccine for Blood Cancer Patients
What You Need to Know Before You Apply
What is the purpose of this trial?
This study evaluates whether the RSV vaccine Abrysvo can produce an antibody response in patients with blood cancers who have previously received a hematopoietic stem cell transplant (HSCT) or CAR-T cell therapy. The vaccine targets the prefusion F (preF) protein of RSV, which is an important component of protective immunity against the virus.
The main goal of the study is to measure the change in antibody levels against the preF protein four weeks after vaccination compared with levels before vaccination. The study will also assess whether participants develop a meaningful immune response, defined as at least a four-fold increase in RSV neutralizing antibody levels four weeks after vaccination.
Are You a Good Fit for This Trial?
This trial is for blood cancer patients who've had a bone marrow transplant or CAR-T cell therapy. It's testing if they can respond to an RSV vaccine called Abrysvo, which aims to boost immunity against the virus.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Respiratory Syncytial Virus Prefusion F Vaccine (RSVpreF)
Trial Overview
The study tests the effectiveness of the RSVpreF vaccine in generating an immune response. Researchers will compare antibody levels before and four weeks after vaccination to see if there's a significant increase.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Patients who will recieve the RSV vaccine
Find a Clinic Near You
Who Is Running the Clinical Trial?
The Cooper Health System
Lead Sponsor
The Cooper Foundation
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.